



Dedicated To Life

July 8, 2022

**BSE Limited**

1<sup>st</sup> Floor,  
P J Towers,  
Dalal Street,  
Mumbai-400001

**Code: 532321**

**National Stock Exchange of India Limited**

Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G Block,  
Bandra-Kurla Complex, Bandra (East),  
Mumbai-400051

**Code: Zyduslife**

**Re.: Press Release**

Dear Sir / Madam,

Please find enclosed a copy of press release dated July 8, 2022 titled "**Zydus has launched Sitaglyn® and Siglyn® (Sitagliptin), for the management of Type 2 diabetes**".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors at large.

Thanking you,

Yours faithfully,

For, **ZYDUS LIFESCIENCES LIMITED**  
(Formerly known as Cadila Healthcare Limited)

**DHAVAL N. SONI**  
**COMPANY SECRETARY**

**Encl.:** As above

**Zydus Lifesciences Limited** (formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,  
S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000  
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878



## **Zydus has launched Sitaglyn® and Siglyn® (Sitagliptin), for the management of Type 2 diabetes**

*Ahmedabad, India, 8 July, 2022*

Zydus Lifesciences Ltd., a discovery-driven global lifesciences company has launched the molecule Sitagliptin in India under the brand names Sitaglyn® and Siglyn® to address Type 2 diabetes in India. Sitaglyn® and Siglyn® will add on to a comprehensive solution for the management of Type 2 diabetes by providing access to quality care to the patients at an affordable cost, approximately 60% lesser than the originator.

Sitaglyn® and Siglyn® offer an oral solution to the patients providing ease of convenience and better compliance. Sitagliptin is the gold standard in the Dipeptidyl peptidase 4 inhibitor (DPP4i) category with over 62% market share in the global market. The drug provides best in class achievement of Hemoglobin A1C (HbA1c) goals with proven safety profile. With more than 77 million active patients, India is the diabetes capital of the world after China. As per the data, 67% of these patients are unable to achieve their HbA1c goal.

Speaking on the development, Dr. Sharvil Patel, Managing Director, Zydus Lifesciences Ltd. said “The addition of Sitaglyn® and Siglyn® to our diabetes portfolio will give patients access to a world-class oral therapy to help people manage their diabetes better by making it more affordable. Our high quality product will expand the reach of the molecule to patients in India, supported by our wide distribution network. The drug will help patients achieve their HbA1C goals reducing the disease burden and providing better patient-care and quality of life.”

India’s oral anti-diabetic market is worth Rs. 125 billion, of which DPP4i class of anti-diabetics has a share of more than Rs. 40 billion. Zydus is amongst the fastest growing players in the diabetes space and has several leading brands to address diabetes including Lipaglyn®, Dapaglyn®, Vinglyn® and Tenglyn®.

With the launch of these brands, Zydus expands its diabetes management offerings for patients and strengthens its presence in the anti-diabetic market.

### **About Zydus**

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs

For further information please contact :  
**The Corporate Communications Department**

**Zydus Lifesciences Limited**  
(formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park',  
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),  
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382  
481, Gujarat, India. | Phone : +91-79-71800000,  
+91-79-48040000 | website : [www.zyduslife.com](http://www.zyduslife.com)  
CIN : L24230GJ1995PLC025878



**PRESS  
RELEASE**



**Dedicated To Life**

over 23000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries. For more details visit [www.zyduslife.com](http://www.zyduslife.com).

\*\*\*\*



**PRESS  
RELEASE**

For further information please contact :  
**The Corporate Communications Department**

**Zydus Lifesciences Limited**  
(formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park',  
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),  
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382  
481, Gujarat, India. | Phone : +91-79-71800000,  
+91-79-48040000 | website : [www.zyduslife.com](http://www.zyduslife.com)  
CIN : L24230GJ1995PLC025878